Bliss GVS Pharma Ltd Share Price

Bliss GVS Pharma are likely to remain in focus on June 3 after the company announced that it has received an Inspection Closure Report from the World Health Organization (WHO), Geneva, for its manufacturing facility in Palghar, Maharashtra. The report confirmed that the facility complies with the Good Manufacturing Practices (GMP) standards prescribed by the WHO, reinforcing the company's commitment to global quality and manufacturing excellence. In the previous trading session, Bliss GVS Pharma shares ended at Rs 434.75, gaining Rs 32.75 or 8.15 percent. The stock touched a 52-week high of Rs 442.20 on June 2, 2026, and a 52-week low of Rs 118.35 on November 10, 2025. At the current market price, the stock is trading 1.68 percent below its 52-week high and has surged 267.34 percent from its 52-week low.

Bliss GVS Pharma Limited is undergoing a major ownership transition, as Anupam Rasayan India Limited has moved to acquire a controlling stake. Anupam Rasayan has signed an agreement to purchase 43.30% of Bliss GVS from existing promoters and select public shareholders at ₹299 per share. Triggering SEBI’s takeover regulations, the acquirer is now launching a mandatory open offer to purchase an additional 26% of the company’s expanded voting share capital from public shareholders at the same ₹299 price. For investors, this acquisition signals a significant shift in corporate leadership, with the acquirer set to become the new promoter and gain full control. While the offer provides an immediate exit opportunity at a fixed cash price, it also marks the end of the current promoter group's tenure. Since the acquirer has stated it has no intention to delist, the company will likely continue its operations under new strategic management.

Anupam Rasayan Expands Pharma Presence With ₹1,369 Crore Bliss GVS Deal

Anupam Rasayan to Acquire 74.20% Stake in Bliss GVS Pharma for ~₹2,199 Crore

Anupam Rasayan India Ltd has approved the acquisition of up to 74.20% equity and control in Bliss GVS Pharma Limited at ₹299 per share, representing a total consideration of approximately ₹2,199 crore. Transaction Structure: Phase 1: Acquisition of 43.30% from identified sellers for ₹1,369.51 crore Open Offer: Up to 26% from public shareholders for ~₹829.03 crore at the same price Future Option: Rights to acquire residual shares from sellers post-closure Timeline: Expected closure within 6 months, subject to regulatory and customary approvals Strategic Rationale: Value Chain Integration: Combines Anupam Rasayan's Key Starting Materials (KSMs) expertise with Bliss GVS's finished dosage forms (suppositories, pessaries, tablets, capsules) — enabling end-to-end pharmaceutical manufacturing. Global Reach: Bliss GVS's presence in 60+ countries accelerates Anupam's international expansion in regulated and semi-regulated markets. Operational Synergies: Shared R&D, supply chain optimization, and cross-selling opportunities expected to enhance margins and revenue visibility. Target Profile (Bliss GVS Pharma): FY26 Turnover: ₹1,000.64 crore (up from ₹798.98 crore in FY24) Net Worth: ₹1,231.76 crore (as of March 31, 2026) Specialization: Niche formulations with strong regulatory compliance track record Outlook: The acquisition marks Anupam Rasayan's strategic entry into finished pharmaceuticals, diversifying beyond specialty chemicals. Successful integration could create a differentiated, vertically integrated platform attractive to global pharma partners.

Multi-Year Breakout After Long Consolidation – Structural Bull Run Ahead?